Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton's Tyrosine Kinase.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
10 Mar 2023
10 Mar 2023
Historique:
received:
05
11
2022
pmc-release:
10
02
2024
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Bruton's tyrosine kinase (BTK) is a target for treating B-cell malignancies and autoimmune diseases. To aid in the discovery and development of BTK inhibitors and improve clinical diagnoses, we have developed a positron emission tomography (PET) radiotracer based on a selective BTK inhibitor, remibrutinib. [
Identifiants
pubmed: 36926452
doi: 10.1021/acsptsci.2c00215
pmc: PMC10012250
doi:
Types de publication
Journal Article
Langues
eng
Pagination
410-421Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB024549
Pays : United States
Organisme : NIBIB NIH HHS
ID : R41 EB029860
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM127253
Pays : United States
Informations de copyright
© 2023 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare the following competing financial interest(s): P.J.T. is the co-founder of Chronus Pharmaceuticals Inc.
Références
Front Immunol. 2021 Nov 03;12:662223
pubmed: 34803999
J Labelled Comp Radiopharm. 2020 Sep;63(11):482-487
pubmed: 32726870
PLoS One. 2016 Jul 19;11(7):e0159607
pubmed: 27434128
Curr Opin Chem Biol. 2019 Jun;50:120-127
pubmed: 31030171
Chem Sci. 2017 May 1;8(5):3434-3443
pubmed: 28507715
Radiology. 2022 Aug;304(2):246-264
pubmed: 35762888
Clin Transl Sci. 2021 Sep;14(5):1756-1768
pubmed: 33834628
J Med Chem. 2022 Jun 9;65(11):7415-7437
pubmed: 35594541
Mol Cancer. 2018 Feb 19;17(1):57
pubmed: 29455639
Anticancer Res. 2021 Nov;41(11):5677-5692
pubmed: 34732441
Bull Math Biol. 2019 Sep;81(9):3508-3541
pubmed: 29230702
Blood. 2011 Jun 16;117(24):6520-31
pubmed: 21482705
J Hematol Oncol. 2013 Aug 19;6:59
pubmed: 23958373
Blood. 2020 Jul 2;136(1):93-105
pubmed: 32202637
Drugs. 2021 Mar;81(4):503-507
pubmed: 33704654
J Nucl Med. 2020 Mar;61(3):437-442
pubmed: 31481582
J Nucl Med. 2019 Apr;60(4):504-510
pubmed: 30389822
J Med Chem. 2020 May 28;63(10):5100-5101
pubmed: 32401033
ACS Chem Neurosci. 2018 Jan 17;9(1):29-39
pubmed: 28640596
J Cell Mol Med. 2009 Jun;13(6):1043-58
pubmed: 18419795
Nat Chem Biol. 2015 Jun;11(6):416-23
pubmed: 25894085
Mol Imaging Biol. 2016 Jun;18(3):386-92
pubmed: 26493053
Eur J Med Chem. 2018 May 10;151:315-326
pubmed: 29631132
Cancers (Basel). 2018 Apr 23;10(4):
pubmed: 29690649
Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8
pubmed: 17684099
Allergy. 2022 Aug;77(8):2355-2366
pubmed: 35175630
Mol Imaging Biol. 2022 Oct;24(5):830-841
pubmed: 35482146
J Med Chem. 2019 Sep 12;62(17):7923-7940
pubmed: 31381333
Int J Mol Sci. 2022 Apr 30;23(9):
pubmed: 35563414
J Med Chem. 2020 Nov 12;63(21):12526-12541
pubmed: 32696648
Anal Chem. 2019 Jul 2;91(13):8443-8452
pubmed: 31247719
N Engl J Med. 2016 Jan 28;374(4):323-32
pubmed: 26641137
J Clin Med. 2022 May 16;11(10):
pubmed: 35628931
J Med Invest. 2004 Feb;51(1-2):14-9
pubmed: 15000251
J Med Chem. 2020 May 28;63(10):5102-5118
pubmed: 32083858
Haematologica. 2018 May;103(5):849-856
pubmed: 29472356
Molecules. 2015 Dec 09;20(12):22000-27
pubmed: 26690113
Nat Rev Cancer. 2014 Apr;14(4):219-32
pubmed: 24658273
Drugs. 2021 Sep;81(14):1605-1626
pubmed: 34609725